Bile Duct Ligation and Recanalization Model

Indication / Application

Preclinical validation of therapeutics targeting hepatic fibrosis regression, evaluation of liver regeneration accelerators, screening of choleretic compounds during recovery, and safety/efficacy testing of biliary reconstructive devices or bio-stents.

Modeling Method

1. Phase 1 - Biliary Obstruction (Ligation): Under high-magnification microsurgery, the common bile duct is isolated and temporarily occluded using specialized micro-clips, loose-tie slipknots, or a micro-cannula loop system to induce uniform intrahepatic cholestasis and early-stage peribiliary fibrosis.

2. Phase 2 - Biliary Decompression (Recanalization): After a calibrated obstruction period (typically 7 to 14 days), a second microsurgery is performed to remove the clip, untie the slipknot, or re-establish anatomical biliary-enteric continuity (via choledochoduodenostomy or cannula removal), allowing immediate restoration of bile flow into the duodenum.

Clinical Relevance

• Fibrosis Resolution Fidelity: Permanent BDL models only capture progressive tissue scarring. Our recanalization model mirrors human clinical interventions (such as gallstone removal or biliary stenting), allowing researchers to study the dynamic, cellular mechanics of spontaneous or drug-induced hepatic fibrosis regression.

• Translational Regeneration Platform: Biliary decompression triggers an immediate, highly synchronized cascade of hepatocyte proliferation and remodeling. Utilizing this platform allows global regulatory submissions (FDA, NMPA, CE) to demonstrate whether an investigational drug actively accelerates functional liver recovery.

Key Evaluation Endpoints

In Vivo / Longitudinal Monitoring

• High-Resolution Micro-Ultrasound: Non-invasive, serial imaging tracking the expansion and subsequent diameter reduction of the common bile duct, along with parenchymal echogenicity shifts.

• Jaundice Remission Tracking: Visual and quantitative evaluation of the resolution of skin/sclera yellowing and normalization of urine coloration post-recanalization.

• Clearance Kinetics: Indocyanine Green (ICG) clearance assays to evaluate the real-time functional recovery of hepatic excretory capacity.

Biochemical Profiling (Serum & Hepatic)

• Reversible Bilirubin Kinetics: Sequential measurement of Total Bilirubin (T-Bil) and Direct Bilirubin (D-Bil) to verify successful surgical decompression.

• Liver Function Normalization Ensembles: Comprehensive profiling of Total Bile Acids (TBA), ALT, AST, ALP, and GGT tracking the clearance rate of cholestatic markers.

Histopathology & Immunohistochemistry 

• Fibrosis Regression Scoring: H&E, Masson’s Trichrome, and Sirius Red staining to quantify the architectural transition from active peribiliary bridging fibrosis to collagen degradation and scar tissue resolution.

• Immunohistochemistry (IHC) & Molecular Profiling:

  • Ductular Reaction Resolution: CK19 tracking to monitor the regression of hyperplastic bile ductules.

  • Stellate Cell Inactivation: alpha-SMA tracking to evaluate the apoptosis or inactivation of scar-forming hepatic stellate cells.

  • Matrix Remodeling Enzymes: Gelatin zymography or Western Blot tracking the balance between Matrix Metalloproteinases (MMPs, e.g., MMP-2, MMP-9) and Tissue Inhibitors of Metalloproteinases (TIMPs).